Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo (TRUST-I)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01576471
Recruitment Status : Completed
First Posted : April 12, 2012
Results First Posted : June 29, 2017
Last Update Posted : June 29, 2017
Information provided by (Responsible Party):
Coronado Biosciences, Inc.

Brief Summary:
This is a randomized, double-blind, placebo-controlled, multicenter, and proof of concept study with a parallel group design to evaluate the safety and efficacy of oral Trichuris Suis Ova (TSO) suspension, as compared to placebo, in patients with moderately to severely active Crohn's disease. This study will also have an optional open-label extension for patients completing the double-blind phase of the study.

Condition or disease Intervention/treatment Phase
Crohn's Disease Biological: Trichuris suis ova (TSO) Biological: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease
Study Start Date : July 2012
Actual Primary Completion Date : October 2013
Actual Study Completion Date : October 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Crohn's Disease

Arm Intervention/treatment
Placebo Comparator: Placebo Biological: Placebo
Placebo: dose every 2 weeks X 10 weeks (up to 6 total doses)

Experimental: TSO 7500 Biological: Trichuris suis ova (TSO)
TSO 7500: 7500 embryonated, viable TSO every 2 weeks X 10 weeks (up to 6 total doses)

Primary Outcome Measures :
  1. Evaluate the Effects of TSO on the Induction of Response in Crohn's Disease, as Measured Primarily by Crohn's Disease Activity Index (CDAI) [ Time Frame: 12 weeks ]
    CDAI >= 100 point reduction from baseline

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient is male or female, 18 to 65 years old.
  2. Patient with established diagnosis of Crohn's disease (CD) for at least 3 months confirmed by endoscopic and histological, or endoscopic and radiological criteria.
  3. Patient with localization of CD either in terminal ileum (L1), in colon (L2) or ileocolitis (L3), all without upper gastrointestinal involvement (- L4) according to the Montreal classification (2005).
  4. Patient with active, symptomatic CD manifested by CDAI ≥ 220 and ≤ 450 at Baseline.
  5. Patient with active intestinal inflammation as visualized by endoscopy within 8 weeks prior to Baseline.
  6. Patient is not using concomitant medication for treatment of underlying Crohn's disease with the following exceptions: concomitant medications may include: 1) Oral or rectal sulfasalazine, mesalazine (5-ASA), or mesalazine derivative, if receiving it for >6 weeks and if receiving the same dose for at least 4 weeks; 2) Oral prednisone up to 15 mg/day, or budesonide if receiving it for >4 weeks and if receiving the same dose for at least 4 weeks; and 3) Azathioprine (up to 2.5 mg/kg daily) or 6-mercaptopurine (up to 2 mg/kg daily) if receiving it for >3 months and if receiving the same dose for at least 8 weeks prior to Baseline.
  7. Hemoglobin of at least 10 g/dl, normal white blood cell and platelet count > lower limit of normal at screening.
  8. For females of childbearing potential, negative serum pregnancy test prior to enrollment, not breastfeeding for study duration, and willingness to use accepted forms of reliable birth control for study duration [including bilateral tubal ligation, use of oral contraceptives, double barrier methods (diaphragm with spermicidal gel or condoms with contraceptive foam), Depo-Provera®, hormonal implants, and total abstinence]. Pregnancy tests are not required (indicate "N/A") for males or females not of childbearing potential (post-menopausal with last menstrual period >1 year ago or total hysterectomy).
  9. Patient has the ability to provide informed consent.

Exclusion Criteria:

  1. Patient with known Crohn's lesions in the upper GI-tract (esophagus, stomach, duodenum, jejunum) with present symptoms.
  2. Patient with ulcerative colitis, indeterminate colitis, or ulcerative proctitis.
  3. Bowel surgery in past 6 months prior to Screening.
  4. Resection of more than 50 cm of the ileum.
  5. Current ileostomy or colostomy.
  6. Ongoing or active septic complications, is hospitalized or exhibiting signs of toxicity (sepsis), has symptomatic strictures, or impending obstruction or anticipating a need for blood transfusion for gastrointestinal bleeding or in whom surgical intervention may be imminent.
  7. Patient with gastrointestinal abscess or perforation.
  8. Patient with fistulae having a new onset within 2 months of Screening with moderate to severe local inflammation.
  9. Patient with history of colorectal cancer or colorectal dysplasia. Patients with completely resected sporadic adenomas may be enrolled.
  10. Patient requiring parenteral or tube feeding.
  11. Patient with current evidence of infectious colitis, e.g., Clostridium difficile, Amoebiasis, Giardia lamblia or stools positive for other enteric pathogens, ova or parasites at Screening.
  12. Female patient who is pregnant or breastfeeding or wishing to become pregnant during study participation or unwilling to use birth control.
  13. Patient with serum creatinine ≥ 2.0 mg/dL; blood urea nitrogen >40 mg/dL; alkaline phosphatase > 250 U/L; aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 100 U/L; or total bilirubin >1.5 mg/dL.
  14. Patient with hepatitis B virus, hepatitis C virus, liver cirrhosis or portal hypertension, or is known to be human immunodeficiency virus (HIV) positive.
  15. Patient with primary sclerosing cholangitis.
  16. Patient with malignancy within the past 5 years, with the exception of completely excised squamous or basal cell skin cancers, and cervical carcinoma in situ.
  17. Patient received cyclosporine, an anti-TNFα or other immunomodulatory agents other than azathioprine/6-mercaptopurine within 12 weeks prior to Screening.
  18. Patient is a primary non-responder an anti-TNFα.
  19. Patient is refractory to azathioprine/6-mercaptopurine.
  20. Patient received methotrexate within 6 weeks prior to Screening.
  21. Patient received metronidazole within 2 weeks prior to Screening.
  22. Patient received non-steroidal anti-inflammatory drugs (NSAIDS) within 2 weeks before Baseline visit for more than 3 consecutive days, except acetylsalicylic acid ≤ 350 mg/d which is allowed.
  23. Patient received antibiotic, antifungal or antiparasitic medication in the last 2 weeks prior to Screening and/or would potentially require this during the study treatment period.
  24. Patient with history of drug or alcohol abuse within 6 months prior to Screening.
  25. Patient with evidence of poor compliance with medical advice and instruction including diet or medication.
  26. Patient is unable or unwilling to swallow study medication suspension.
  27. Patient with a significant medical condition which puts the patient at risk for study participation and/or for any reason is considered by the Investigator to be an unsuitable patient to receive CNDO-201 TSO or is potentially put at risk by study procedures.
  28. Patient who has participated in another clinical trial within 30 days of Screening for this trial and/or any experimental treatment for this population.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01576471

  Hide Study Locations
United States, Arizona
Visions Clinical Research - Tucson
Tucson, Arizona, United States, 85712
United States, Arkansas
Lynn Institue of the Ozarks
Little Rock, Arkansas, United States, 72205
Preferred Research Partners
Little Rock, Arkansas, United States, 72211
United States, California
Anaheim Clinical Trials
Anaheim, California, United States, 92801
Rokay Kamyar, MD Inc
La Mesa, California, United States, 91941
Medvin Clinical Research
La Mirada, California, United States, 90638
Lakewood Primary Care Medical Group, Inc
Lakewood, California, United States, 90712
Alliance Research
Long Beach, California, United States, 90804
Collaborative Neuroscience Network, Inc.
Long Beach, California, United States, 90806
Alliance Clinical Research, LLC
Oceanside, California, United States, 92056
Digestive Care Associates
San Carlos, California, United States, 94070
San Diego Clinical Trials
San Diego, California, United States, 92120
United States, Colorado
Gastroenterology of the Rockies
Lafayette, Colorado, United States, 80026
United States, Florida
Clinical Research of West Florida
Clearwater, Florida, United States, 33765
Sanitas Research
Coral Gables, Florida, United States, 33134
Avail Clinical Research, LLC
DeLand, Florida, United States, 32720
Florida Medical Research Institute
Gainesville, Florida, United States, 32607
The Center for Gastrointestinal Disorders
Hollywood, Florida, United States, 33021
Borland-Groover Clinic
Jacksonville, Florida, United States, 32204
Gastroenterology Associates of Osceola
Kissimmee, Florida, United States, 34741
Sunrise Medical Research
Lauderdale Lakes, Florida, United States, 33319
Paramount Public Health & Research Management Services
Miami, Florida, United States, 33135
Community Research Foundation, Inc
Miami, Florida, United States, 33155
Gastroenterology Group of Naples
Naples, Florida, United States, 34102
Clinical Research of West Florida, Inc.
Tampa, Florida, United States, 336003
Shafran Gastroenterology Center
Winter Park, Florida, United States, 32789
United States, Georgia
Atlanta Gastroenterology Specialists, PC
Suwanee, Georgia, United States, 30024
United States, Idaho
Selah Medical Center
Boise, Idaho, United States, 83704
United States, Illinois
Northwest Gastroenterologists
Arlington Heights, Illinois, United States, 60005
Suburban Clinical Research
Bolingbrook, Illinois, United States, 60490
Suburban Clinical Research
Burr Ridge, Illinois, United States, 60527
The University of Chicago Hospital
Chicago, Illinois, United States, 60637
United States, Indiana
Medisphere Medical Research Center, LLC
Evansville, Indiana, United States, 47714
United States, Iowa
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States, 52242
United States, Kansas
Cotton O'Neil Digestive Healthcare
Topeka, Kansas, United States, 66606
United States, Kentucky
University of Louisville
Louisville, Kentucky, United States, 40202
United States, Massachusetts
Tufts Medical Center
Boston, Massachusetts, United States, 02111
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
United States, Michigan
University of Michigan Health Services
Ann Arbor, Michigan, United States, 48109
Clinical Research Institute of Michigan, LLC
Chesterfield, Michigan, United States, 48047
Beyer Research
Kalamazoo, Michigan, United States, 49009
United States, Missouri
Midwest Center for Clinical Research
Lee's Summit, Missouri, United States, 64064
Center for Digestive and Liver Disease
Mexico, Missouri, United States, 65265
United States, Montana
Billings Clinic Research Center
Billings, Montana, United States, 59101
United States, Nebraska
Quality Clinical Research, Inc.
Omaha, Nebraska, United States, 68114
United States, Nevada
Reno Clinical Trials
Sparks, Nevada, United States, 89434
United States, New Jersey
South Jersey Medical Associates, P.A.
Blackwood, New Jersey, United States, 08012
Holy Name Medical Center
Teaneck, New Jersey, United States, 07666
United States, New York
Albany Medical Center
Albany, New York, United States, 12208
Digestive Health Physicians
Cheektowaga, New York, United States, 14225
Long Island Clinical Research Associates, LLP
Great Neck, New York, United States, 11021
Metropolitan Research Associates
New York, New York, United States, 10016
United States, North Carolina
University of North Carolina
Chapel Hill, North Carolina, United States, 27599
Clinical Trials of America, Inc.
Winston-Salem, North Carolina, United States, 27103
United States, Ohio
Consultants for Clinical Research, Inc
Cincinnati, Ohio, United States, 45219
The Ohio State University-Inflammatory Bowel Disease Ctr
Columbus, Ohio, United States, 43210
Great Lakes Gastroenterology
Mentor, Ohio, United States, 44060
United States, Oklahoma
Gastroenterology United of Tulsa
Tulsa, Oklahoma, United States, 74135
United States, Oregon
Northwest Gastroenterology Clinic, LLD
Portland, Oregon, United States, 97210
United States, Pennsylvania
James J. Boylan Gastroenterology and Liver Diseases
Bethlehem, Pennsylvania, United States, 18015
Shirish A. Amin, MD, PC
Indiana, Pennsylvania, United States, 15701
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213
Donald Guthrie Foundation for Education & Research
Sayre, Pennsylvania, United States, 18840
Cherry Tree Medical
Uniontown, Pennsylvania, United States, 15401
United States, Rhode Island
Omega Medical Research
Warwick, Rhode Island, United States, 02886
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37212
United States, Texas
Austin Gastroenterology PA/Professional Quality Research, Inc
Austin, Texas, United States, 78705
Lovelace Scientific Resources, Inc.
Austin, Texas, United States, 78758
Diagnostic Clinic of Houston
Houston, Texas, United States, 77004
Baylor College of Medicine
Houston, Texas, United States, 77030
United States, Virginia
Gastroenterology Associates of Northern Virginia
Fairfax, Virginia, United States, 22031
Virginia Commonwealth University Medical Center
Richmond, Virginia, United States, 23298
United States, Washington
Wenatchee Valley Medical Center
Wenatchee, Washington, United States, 98801
Sponsors and Collaborators
Coronado Biosciences, Inc.
Study Director: Nova Silver Coronado Biosciences

Responsible Party: Coronado Biosciences, Inc. Identifier: NCT01576471     History of Changes
Other Study ID Numbers: CNDO 201-003
First Posted: April 12, 2012    Key Record Dates
Results First Posted: June 29, 2017
Last Update Posted: June 29, 2017
Last Verified: April 2017

Keywords provided by Coronado Biosciences, Inc.:
T. suis ova
Trichuris suis ova
Inflammatory Bowel Disease

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases